Bone Therapeutics to Strategically Focus on ALLOB Cell Therapy

Bone Therapeutics is redefining its strategic priorities to concentrate specifically on the development of the allogeneic cell therapy platform, ALLOB.

ALLOB is Bone Therapeutics’ off-the-shelf allogeneic cell therapy platform comprising human allogeneic bone-forming cells derived from cultured bone marrow mesenchymal stromal cells from healthy...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us